Updated review on targeting KRAS in NSCLC
Stephen V Liu shared on X:
“Updated review on targeting KRAS in NSCLC available in Lung Cancer Journal. Looking beyond the approved sotorasib and adagrasib, what advantages could the next generation of agents bring to KRAS G12C and non-G12C? What combinations show the most promise?”
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Authors: Yuko Oya, Kazuyoshi Imaizumi and Tetsuya Mitsudomi.
Source: Stephen V Liu/X
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.
His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.